Firm
Firms that made strategic PTAB hires say that insider expertise is becoming more valuable in the wake of USPTO changes
Aled Richards-Jones, a litigator and qualified barrister, is the fourth partner to join the firm’s growing patent litigation team this year
An IP lawyer tasked with helping to develop Brownstein’s newly unveiled New York office is eyeing a measured approach to talent hunting
Edward Russavage and Maria Crusey at Wolf Greenfield say that OpenAI MDL could broaden discovery and reshape how clients navigate AI copyright disputes
Sponsored
Sponsored
-
Sponsored by Berken IPMaría Aurora García of Berken IP explains how Argentina’s evolving non-use cancellation system strengthens trademark integrity, streamlines registration, and promotes fairer market competition through efficient, partial, and administrative cancellation mechanisms -
Sponsored by TOPPAN Digital IPManaging IP hears how TOPPAN Digital IP’s platform aims to streamline global patent management, combining artificial intelligence and human expertise to facilitate efficient filings, accurate translations, and smooth renewals in a single, secure environment
-
Sponsored by Licks AttorneysHow UK extraterritorial decisions are undermining Brazilian judicial sovereignty and violating TRIPSSenior patent attorneys at Licks Attorneys say recent UK court decisions on FRAND licensing conflict with Brazilian judicial sovereignty and the TRIPS framework governing the territorial independence of patents
-
Sponsored by Gün and PartnersSelin Sinem Erciyas of Gün + Partners explores the growing alignment between Turkish courts and the Unified Patent Court in applying a strictly technical-functional standard for patent infringement by equivalence
-
Sponsored by Liu, Shen & AssociatesWenjing Zhu of Liu, Shen & Associates explains how China’s administrative adjudication system is reshaping patent enforcement, offering faster, cost-effective, and technically expert resolutions for patentees, while preserving rights to pursue court remedies
-
Sponsored by Wanhuida Intellectual PropertyMinnan (Miranda) Xie of Wanhuida Intellectual Property analyses how China’s patent authorities and courts assess second medical use inventions, with key CNIPA decisions clarifying the treatment of dosage regimens and patient subgroups in novelty determinations
